Although Ki67 index suffers from poor reproducibility, it is one of the most important
prognostic markers used by oncologists to select the treatment of estrogen receptor (ER) …

A proliferative marker, expressed as the percentage of cells in a cell cycle, has been
developed and used as a discriminant of more aggressive malignant phenotypes in early …

Purpose The proliferation-associated biomarker Ki67 has potential utility in breast cancer,
including aiding decisions based on prognosis, but has unacceptable inter-and …

Introduction Breast cancer is a heterogeneous disease. Our study focuses on a
monoinstitutional series of patients affected by Hormone Responsive carcinomas (luminal A …

Clinicians can use biomarkers to guide therapeutic decisions in estrogen receptor positive
(ER+) breast cancer. One such biomarker is cellular proliferation as evaluated by Ki-67. This …

The Ki-67 index is an important biomarker for indicating the proliferation of cancer cells and
is considered to be an effective prognostic factor for breast cancer. However, a standard cut …

The proliferation marker Ki-67 is one of the most controversially discussed parameters for
treatment decisions in breast cancer patients. The purpose of this study was to evaluate the …

Abstract Ki67 immunohistochemistry (IHC), commonly used as a proliferation marker in
breast cancer, has limited value for treatment decisions due to questionable analytical …

The aim of this study was to evaluate the prognostic value of Ki67 in relation to established
prognostic factors in lymph node-negative breast cancer, and furthermore, whether the …

Objectives Ki67 is the most commonly used marker to evaluate proliferative index in breast
cancer, however no cutoff values have been clearly defined for high ki67 index. Cancer …